Purified anti-C/EBPalpha Antibody anti-C/EBPalpha - 16C12B70,BioLegend,662102

This product weakly reacts with Mouse.

Host

Mouse

Reactivity

Human

Application

WB -Quality testedICC -Verified

Platform ID

BAB856202143

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NamePurified anti-C/EBPalpha Antibody anti-C/EBPalpha - 16C12B70
Cat. No.662102
HostMouse
RRIDAB_2564224 (BioLegend Cat. No. 662102)
IsotypeMouse IgG2a, κ
ReactivityHuman
ApplicationWB -Quality testedICC -Verified
ClonalityMonoclonal
Clone Number16C12B70
Concentration0.5 mg/mL
TargetC/EBPalpha
ImmunogenSynthetic peptide (AKQLALAGLFPYQPPPP) conjugated to KLH.
PurityThe antibody was purified by affinity chromatography.
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
StorageThe antibody solution should be stored undiluted between 2°C and 8°C.
Regulatory StatusResearch Use Only

Scientific Background

The CCAAT-enhancer binding proteins (C/EBP) are members of the basic region/leucine zipper (bZIP) transcription factors, that bind to the consensus CCAAT sequence in DNA. C/EBPα is expressed in two isoforms: p42 and p30 by ultilizing different translational start codons. The C/EBPα p30 isoform has little to no transactivating activity and acts as an inhibitor. C/EBPα regulates expression of various myeloid-specific genes and is required for myeloid differentiation. C/EBPα has been found to play a key role in adipogenesis, since inhibition of C/EBPα blocks adipocyte differentiation. C/EBPα also regulates cell cycle progression through interactions with cyclin-dependent kinases (CDK) and by inducing the expression of CDK inhibitor p21. Mutations in the C/EBPα gene are associated with the development of acute myeloid leukemia.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.